AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the Children's Oncology Group

Cancer

Volumn 118, Issue 3, 2012, Pages 761-769

  Cooper, Todd M ^a   Franklin, Janet ^b   Gerbing, Robert B ^c   Alonzo, Todd A ^d   Hurwitz, Craig ^e   Raimondi, Susana C ^f   Hirsch, Betsy ^g   Smith, Franklin O ^h   Mathew, Prasad ⁱ   Arceci, Robert J ^j   Feusner, James ^k   Iannone, Robert ^l   Lavey, Robert S ^m   Meshinchi, Soheil ⁿ   Gamis, Alan ^o  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Aslettas Pharmaceuticals   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF CINCINNATI   (United States)

ⁱ UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^j JOHNS HOPKINS HOSPITAL   (United States)

^k Children's Research Hospital of Oakland   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁿ USA   (United States)

^o CHILDREN S MERCY HOSPITAL   (United States)

more..

Author keywords

AAML03P1; childhood acute myeloid leukemia; children; gemtuzumab ozogamicin; newly diagnosed

Indexed keywords

ALANINE AMINOTRANSFERASE; AMSACRINE; ASPARAGINASE; ASPARTATE AMINOTRANSFERASE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; HLA MATCHING; HUMAN; HUMAN CELL; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOTENSION; INFANT; INFECTION; LEUKEMIA REMISSION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AMINOGLYCOSIDES; AMSACRINE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 80055064760     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26190     Document Type: Article

References (30)

1. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in 4 consecutive AML-BFM trials. Leukemia. 2005; 19: 2030-2042.
2. Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ,. Long-term results of children with acute myeloid leukemia: a report of 3 consecutive phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005; 19: 2054-2062.
3. Kardos G, Zwaan CM, Kaspers GJ, et al. Treatment strategy and results in children treated on 3 Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia. 2005; 19: 2063-2071.
4. Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia. 2005; 19: 2082-2089.
5. Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005; 19: 2130-2138.
6. Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of 4 consecutive childhood AML trials conducted between 1981 and 2000. Leukemia. 2005; 19: 2101-2116.
7. Ribeiro RC, Razzouk BI, Pounds S, Hijiya N, Pui CH, Rubnitz JE,. Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia. 2005; 19: 2125-2129.
8. Lie SO, Abrahamsson J, Clausen N, et al. Long-term results in children with AML: NOPHO-AML Study Group-report of 3 consecutive trials. Leukemia. 2005; 19: 2090-2100.
9. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009; 27: 4007-4013.
10. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010; 11: 543-552.
11. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996; 87: 4979-4989.
12. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008; 111: 1044-1053.
13. Ikemoto N, Kumar RA, Ling TT, Ellestad GA, Danishefsky SJ, Patel DJ,. Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc Natl Acad Sci U S A. 1995; 92: 10506-10510.
14. Reinhardt D, Diekamp S, Fleischhack G, et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie. 2004; 27: 269-272.
15. Zwaan CM, Reinhardt D, Jurgens H, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia. 2003; 17: 468-470.
16. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003; 102: 4277-4283.
17. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005; 104: 1442-1452.
18. Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 2005; 106: 1183-1188.
19. Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2008; 26: 2390-2395.
20. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001; 19: 3244-3254.
21. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993; 118: 255-267.
22. Petersdorf S, Kopecky KJ, Stuart R, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. Blood. 2009; 114: 790.
23. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011; 29: 369-377.
24. Wells RJ, Adams MT, Alonzo TA, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol. 2003; 21: 2940-2947.
25. Liu Yin JA, Wheatley K, Rees JK, Burnett AK,. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol. 2001; 113: 713-726.
26. McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin- associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007; 31: 599-604.
27. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003; 102: 1578-1582.
28. Litzow MR, Repoussis PD, Schroeder G, et al. Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. Leuk Lymphoma. 2002; 43: 2099-2107.
29. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999; 107: 69-79.
30. Pocock SJ,. The combination of randomized and historical controls in clinical trials. J Chronic Dis. 1976; 29: 175-188.